The potential for stem cells in cerebral palsy-piecing together the puzzle

Seminars in Pediatric Neurology

Volumn 20, Issue 2, 2013, Pages 146-153

  Faulkner, Stuart D ^a,b,c   Ruff, Crystal A ^a,b,c   Fehlings, Michael G ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BACLOFEN; BOTULINUM TOXIN A; ERYTHROPOIETIN; HYALURONIC ACID; MOLECULAR SCAFFOLD; POLYMER; BOTULINUM TOXIN;

ADULT STEM CELL; ARTICLE; ATAXIA; BIOENGINEERING; CELL TYPE; CEREBRAL PALSY; CLINICAL TRIAL (TOPIC); CONFUSION; CONSTRAINT INDUCED MOVEMENT THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; DIZZINESS; DRUG TARGETING; DYSTONIA; EMBRYONIC STEM CELL; EPIGENETICS; GAME; GENETIC VARIABILITY; GLIA CELL; HUMAN; HYPOTENSION; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOVEMENT THERAPY; NAUSEA; NERVE CELL DIFFERENTIATION; NONHUMAN; OCCUPATIONAL THERAPY; PARESTHESIA; PHYSIOTHERAPY; PLAY THERAPY; PLURIPOTENT STEM CELL; SOMNOLENCE; SPASTICITY; STEM CELL TRANSPLANTATION; TRANSCRANIAL MAGNETIC STIMULATION; WEAKNESS; BIOLOGICAL THERAPY; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES; RECREATION; TISSUE SCAFFOLD;

BACLOFEN; BOTULINUM TOXINS; CELL- AND TISSUE-BASED THERAPY; CEREBRAL PALSY; COMBINED MODALITY THERAPY; EXERCISE THERAPY; HUMANS; OCCUPATIONAL THERAPY; PHYSICAL THERAPY MODALITIES; STEM CELL TRANSPLANTATION; TISSUE SCAFFOLDS; TRANSCRANIAL MAGNETIC STIMULATION; VIDEO GAMES;

EID: 84881524062     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2013.06.002     Document Type: Article

References (83)

1. Patoine B. NerveCenter: media focus on "miracle cure" for cerebral palsy pits science vs. hype. Ann Neurol 2009, 66:A9-A11.
2. Wu Y.W., Colford J.M. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. J Am Med Assoc 2000, 284:1417-1424.
3. Crichton J.U., Dunn H.G., McBurney A.K., Robertson A.M., Tredger E. Long-term effects of neonatal jaundice on brain function in children of low birth weight. Pediatrics 1972, 49:656-670.
4. Gordon A.L., English M., Tumaini Dzombo J., Karisa M., Newton C.R. Neurological and developmental outcome of neonatal jaundice and sepsis in rural Kenya. Trop Med Int Health 2005, 10:1114-1120.
5. Lawn J.E., Cousens S., Zupan J. 4 million neonatal deaths: when? Where? Why?. Lancet 2005, 365:891-900.
6. Burd I., Bentz A.I., Chai J., et al. Inflammation-induced preterm birth alters neuronal morphology in the mouse fetal brain. J Neurosci Res 2010, 88:1872-1881.
7. Zupan V., Gonzalez P., Lacaze-Masmonteil T., et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 1996, 38:1061-1067. [cited Jan 15, 2013].
8. Meyer U., Nyffeler M., Engler A., et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 2006, 26:4752-4762.
9. Burd I., Balakrishnan B., Kannan S. Models of fetal brain injury, intrauterine inflammation, and preterm birth. Am J Reprod Immunol 2012, 67:287-294. [cited Nov 1, 2012].
10. Fern R., Moller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci 2000, 20:34-42. [cited May 24, 2010].
11. Itoh T., Beesley J., Itoh A., et al. AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem 2002, 81:390-402.
12. Back S.A., Luo N.L., Mallinson R.A., et al. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol 2005, 58:108-120. [cited Aug 4, 2011].
13. Palisano R.J., Begnoche D.M., Chiarello L.A., Bartlett D.J., McCoy S.W., Chang H.J. Amount and focus of physical therapy and occupational therapy for young children with cerebral palsy. Phys Occup Ther Pediatr 2012, 32:368-382.
14. Gordon A.M., Chinnan A., Gill S., Petra E., Hung Y.C., Charles J. Both constraint-induced movement therapy and bimanual training lead to improved performance of upper extremity function in children with hemiplegia. Dev Med Child Neurol 2008, 50:957-958. [cited Dec 13, 2012].
15. Gordon A.M., Hung Y.-C., Brandao M., et al. Bimanual training and constraint-induced movement therapy in children with hemiplegic cerebral palsy: a randomized trial. Neurorehabil Neural Repair 2011, 25:692-702.
16. Charles J.R., Gordon A.M. A repeated course of constraint-induced movement therapy results in further improvement. Dev Med Child Neurol 2007, 49:770-773. [cited Dec 13, 2012].
17. Biddiss E., Irwin J. Active video games to promote physical activity in children and youth: a systematic review. Arch Pediatr Adolesc Med 2010, 164:664-672.
18. Dralle D., Müller H., Zierski J., Klug N. Intrathecal baclofen for spasticity. Lancet 1985, 326:1003. [cited Nov 21, 2012].
19. Goldstein E.M. Spasticity management: an overview. J Child Neurol 2001, 16:16-23.
20. Bakheit A.M., Severa S., Cosgrove A., et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001, 43:234-238.
21. Kawamura A., Campbell K., Lam-Damji S., Fehlings D. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 2007, 49:331-337.
22. Wassermann E.M. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998, 108:1-16.
23. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676. [cited May 2, 2010].
24. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872. [cited May 7, 2010].
25. Gore A., Li Z., Fung H.-L., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
26. Woltjen K., Michael I.P., Mohseni P., et al. iggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770. [cited Feb 18, 2010].
27. Loh Y.-H., Yang J.C., De Los Angeles A., et al. Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. Curr Protoc Stem Cell Biol 2012, [Chapter 4: Unit 4A.5].
28. Warren L., Manos P.D., Ahfeldt T., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:1-13.
29. Ichida J.K., Blanchard J., Lam K., et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5:491-503. [cited May 9, 2010].
30. Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B 2009, 85:348-362.
31. Wen B., Wu H., Loh Y.-H., Briem E., Daley G.Q., Feinberg A.P. Euchromatin islands in large heterochromatin domains are enriched for CTCF binding and differentially DNA-methylated regions. BMC Genomics 2012, 13:566.
32. Kim K., Zhao R., Doi A., et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011, 29:1117-1119.
33. Kim K., Doi A., Wen B., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
34. Koga H., Muneta T., Nagase T., et al. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. Cell Tissue Res 2008, 333:207-215.
35. Deng J., Shoemaker R., Xie B., et al. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009, 27:353-360. [cited Jun 20, 2010].
36. Rowland JW, Lee JJ, Salewski RP, Eftekharpour E, van der Kooy D, Fehlings MG: Generation of neural stem cells from embryonic stem cells using the default mechanism: in vitro and in vivo characterization. Stem Cells Dev 20:1829-1845, 2011.[cited Sep 20, 2011]. http://www.ncbi.nlm.nih.gov/pubmed/21604925.
37. Smukler S.R., Runciman S.B., Xu S., van der Kooy D. Embryonic stem cells assume a primitive neural stem cell fate in the absence of extrinsic influences. J Cell Biol 2006, 172:79-90. [cited May 2, 2010].
38. Marro S., Pang Z.P., Yang N., et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell 2011, 9:374-382.
39. Rouaux C., Arlotta P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat Cell Biol 2013, 15:214-221.
40. Montana C.L., Kolesnikov A.V., Shen S.Q., Myers C.A., Kefalov V.J., Corbo J.C. Reprogramming of adult rod photoreceptors prevents retinal degeneration. Proc Natl Acad Sci USA 2013, 110:1732-1737.
41. Ruff C.A., Fehlings M.G. Neural stem cells in regenerative medicine: bridging the gap. Panminerva Med 2010, 52:125-147. [cited Jun 8, 2010].
42. Kobayashi Y., Okada Y., Itakura G., et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS ONE 2012, 7:e52787.
43. Karimi-Abdolrezaee S., Eftekharpour E., Wang J., Morshead C.M., Fehlings M.G. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 2006, 26:3377-3389. [cited May 10, 2010].
44. Karimi-Abdolrezaee S., Eftekharpour E., Wang J., Schut D., Fehlings M.G. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci 2010, 30:1657-1676. [cited Mar 15, 2010].
45. Windrem M.S., Schanz S.J., Guo M., et al. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell 2008, 2:553-565. [cited Feb 18, 2010].
46. Obenaus A., Dilmac N., Tone B., et al. Long-term magnetic resonance imaging of stem cells in neonatal ischemic injury. Ann Neurol 2011, 69:282-291. [cited Jul 4, 2011].
47. Fujimoto Y, Abematsu M, Falk A, et al: Treatment of a mouse model of spinal cord injury by transplantation of human iPS cell-derived long-term self-renewing neuroepithelial-like stem cells. Stem Cells 30:1163-1173, 2012.
48. Zawadzka M., Rivers L.E., Fancy S.P.J., et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 2010, 6:578-590. [cited Oct 14, 2010].
49. Hunt J., Cheng A., Hoyles A., Jervis E., Morshead C.M. Cyclosporin A has direct effects on adult neural precursor cells. J Neurosci 2010, 30:2888-2896.
50. Wang J., Gallagher D., DeVito L.M., et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012, 11:23-35.
51. Goldman S.A., Nedergaard M., Windrem M.S. Glial progenitor cell-based treatment and modeling of neurological disease. Science 2012, 338:491-495.
52. Erices A., Conget P., Minguell J.J. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000, 109:235-242.
53. Nieda M., Nicol A., Denning-Kendall P., Sweetenham J., Bradley B., Hows J. Endothelial cell precursors are normal components of human umbilical cord blood. Br J Haematol 1997, 98:775-777.
54. Barbero A., Ploegert S., Heberer M., Martin I. Plasticity of clonal populations of dedifferentiated adult human articular chondrocytes. Arthritis Rheum 2003, 48:1315-1325. [cited Oct 2, 2010].
55. Battula V.L., Bareiss P.M., Treml S., et al. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 2007, 75:279-291. [cited Oct 2, 2010].
56. De Bari C., Dell'Accio F., Tylzanowski P., Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001, 44:1928-1942. [cited Oct 2, 2010].
57. Weiss M.L., Medicetty S., Bledsoe A.R., et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006, 24:781-792. [cited Oct 2, 2010].
58. Zuk P.A., Zhu M., Mizuno H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228. [cited Oct 2, 2010].
59. Isa A, Nehlin JO, Sabir HJ, et al: Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors. 2010 May 28;5(5):e10900. doi: 10.1371/journal.pone.0010900. PubMed PMID: 20531935; PubMed Central PMCID: PMC2878340.
60. Liao W., Xie J., Zhong J., et al. Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation 2009, 87:350-359. [cited May 11, 2010].
61. Chen J., Zhang Z.G., Li Y., et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 2003, 92:692-699. [cited May 11, 2010].
62. Prockop D.J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009, 17:939-946. [cited Oct 2, 2010].
63. Meletis K., Frisén J. Blood on the tracks: a simple twist of fate?. Trends Neurosci 2003, 26:292-296. [cited May 12, 2010].
64. Bennet L., Tan S., Van den Heuij L., et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Ann Neurol 2012, 71:589-600. [cited Jan 15, 2013].
65. Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today 2002, 38:103-111.
66. Pearse D.D., Sanchez A.R., Pereira F.C., et al. Transplantation of Schwann cells and/or olfactory ensheathing glia into the contused spinal cord: survival, migration, axon association, and functional recovery. Glia 2007, 55:976-1000. [cited May 7, 2010].
67. Duncan I.D., Aguayo A.J., Bunge R.P., Wood P.M. Transplantation of rat Schwann cells grown in tissue culture into the mouse spinal cord. J Neurol Sci 1981, 49:241-252.
68. Raisman G. Use of Schwann cells to induce repair of adult CNS tracts. Rev Neurol 1997, 153:521-525. [cited Oct 10, 2010].
69. Campbell G., Hutchins K., Winterbottom J., Grenningloh G., Lieberman A.R., Anderson P.N. Upregulation of activating transcription factor 3 (ATF3) by intrinsic CNS neurons regenerating axons into peripheral nerve grafts. Exp Neurol 2005, 192:340-347.
70. Mackay-Sim A,., John J.A. Olfactory ensheathing cells from the nose: clinical application in human spinal cord injuries. Exp Neurol 2011, 229:174-180.
71. Chen G., Hu Y., Wan H., et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells and Schwann cells. Chin Med J 2010, 123:2424-2431.
72. Home-ClinicalTrials.gov [Internet]. ; [cited Jan 15, 2013]. http://www.clinicaltrials.gov/.
73. StemCells, Inc.[U+202F]: Groundbreaking Science. Breakthrough Medicine [Internet]. ; [cited Jan 17, 2013]. http://www.stemcellsinc.com/.
74. StemCells finds early data from spinal cord injury trial promising-San Francisco Business Times [Internet]. ; [cited Sep 20, 2012]. http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/09/stemcells-neural-stem-cells-spinal-cord.html.
75. Lau D., Ogbogu U., Taylor B., Stafinski T., Menon D., Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008, 3:591-594.
76. Hwang D.H., Kim H.M., Kang Y.M., et al. Combination of multifaceted strategies to maximize the therapeutic benefits of neural stem cell transplantation for spinal cord repair. Cell Transplant 2011, 20:1361-1379.
77. Prestwich G.D. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 2011, 155:193-199.
78. Wang Y., Wei Y.T., Zu Z.H., et al. Combination of hyaluronic acid hydrogel scaffold and PLGA microspheres for supporting survival of neural stem cells. Pharm Res 2011, 28:1406-1414.
79. Wang L., Shansky J., Borselli C., Mooney D., Vandenburgh H. Design and fabrication of a biodegradable, covalently crosslinked shape-memory alginate scaffold for cell and growth factor delivery. Tissue Eng 2012, 18:2000-2007.
80. Tysseling-Mattiace V.M., Sahni V., Niece K.L., et al. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J Neurosci 2008, 28:3814-3823. [cited Dec 18, 2009].
81. Leung G.K.K., Wang Y.C., Wu W. Peptide nanofiber scaffold for brain tissue reconstruction. Meth Enzymol 2012, 508:177-190.
82. Wright P.A., Durham S., Ewins D.J., Swain I.D. Neuromuscular electrical stimulation for children with cerebral palsy: a review. Arch Dis Child 2012, 97:364-371.
83. Bolognini N., Vallar G., Casati C., et al. Neurophysiological and behavioral effects of tDCS combined with constraint-induced movement therapy in poststroke patients. Neurorehabil Neural Repair 2011, 25:819-829.